Abstract
Objectives
To compare focal-type autoimmune pancreatitis (AIP) and pancreatic ductal adenocarcinoma (PDA) using contrast-enhanced MR imaging (CE-MRI), and to assess diagnostic performance of the lesion contrast at arterial phase (AP) (ContrastAP) for differentiating between the two diseases.
Methods
Thirty-six patients with focal-type AIP and 72 patients with PDA were included. All included patients underwent CE-MRI with triple phases. The signal intensity (SI) of the mass and normal pancreas was measured at each phase, and the lesion contrast (SIpancreas/SImass) was compared between AIP and PDA groups. The sensitivity and specificity of ContrastAP using an optimal cutoff point were compared with those of key imaging features specific to AIP and PDA.
Results
The lesion contrast differed significantly between AIP and PDA groups at all phases of CE-MRI; the maximum difference was observed at AP. For AIP, the sensitivity (94.4%) and specificity (87.5%) of ContrastAP (cutoff ≤ 1.41) were comparable or significantly higher than those of all key imaging features (sensitivity, 38.9–88.9%; specificity, 48.6–95.8%), except for the halo sign. For PDA, the sensitivity (87.5%) and specificity (94.4%) of ContrastAP (cutoff > 1.41) were comparable or significantly higher than those of all key imaging features (sensitivity, 40.3–68.1%; specificity, 72.2–94.4%), except for the discrete mass.
Conclusions
Quantitative analysis of the lesion contrast using CE-MRI, particularly at AP, was helpful to differentiate focal-type AIP from PDA. The diagnostic performance of ContrastAP was mostly comparable or higher than those of the key imaging features.
Key Points
• Diagnosis of focal-type AIP vs. PDA using imaging techniques is extremely challenging.
• Lesion contrast in the arterial-phase MRI differs significantly between focal-type AIP and PDA.
• Quantitative analysis of lesion contrast using CE-MRI, particularly at the arterial phase, is helpful to differentiate focal-type AIP from PDA.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Autoimmune pancreatitis (AIP) is a rare but distinctive type of chronic pancreatitis, which responds dramatically well to steroid therapy [1]. AIP can mimic pancreatic ductal adenocarcinoma (PDA), and characterization is important to avoid unnecessary surgery in patients with AIP [2,3,4,5]. Non-diffuse-type (i.e., focal and multifocal-type) AIP is challenging while diffuse-type AIP commonly manifests as a characteristic “sausage-like” pancreatic swelling, very different from PDA [2,3,4]. In multifocal-type AIP, magnetic resonance imaging (MRI) clearly demonstrates multiple pancreatic masses and multiple pancreatic duct strictures, highly specific for AIP [6]. Conversely, focal-type AIP, representing 28–48% of all AIP [7,8,9,10], is very difficult to differentiate from PDA as both diseases manifest as a single focal pancreatic mass and pancreatic duct stricture.
Attempts to differentiate focal-type AIP and PDA have been reported using computed tomography (CT) or MRI [11,12,13,14,15,16,17,18]. Some key differentiating features with regard to morphology of the pancreatic mass and pattern of the pancreatic duct stricture were identified. Several studies assessed the dynamic enhancement pattern of focal-type AIP using contrast-enhanced MRI (CE-MRI) mostly focused on the delayed enhancement [11,12,13,14]. The enhancement pattern at the arterial phase (AP) received little attention. Few studies have described merely “hypointensity” of focal-type AIP at the AP [11,12,13]. However, we observed in daily practice a clear difference in enhancement pattern or lesion contrast at the AP between focal-type AIP and PDA. Therefore, we initiated this study to compare quantitatively the lesion contrast between focal-type AIP and PDA using CE-MRI with an emphasis on the AP, and we assessed the diagnostic performance of the lesion contrast at the AP for differentiating between the two diseases.
Materials and methods
Study population
This retrospective study was approved by our institutional review board; patient informed consent was waived. In our institution’s medical database, we identified 169 patients diagnosed with AIP according to the Asian criteria [19], HISORt criteria [20], or international consensus diagnostic criteria [21] between January 2007 and December 2016 (Fig. 1). Among these, we finally included 36 patients (21 men, 15 women; mean age ± standard deviation, 56.7 ± 11.6 years (range, 18–75 years)) based on the following inclusion criteria: (a) the presence of CE-MRI, including unenhanced (UP), arterial (AP), portal (PP), and delayed (DP) phases before steroid treatment; (b) focal-type AIP; (c) the absence of obvious extrapancreatic organ involvement, including sclerosing cholangitis, renal involvement, and retroperitoneal fibrosis, potentially affecting blinded image interpretation; and (d) the presence of normal pancreatic parenchyma with normal-appearing signal intensity (SI) on T1-weighted images, which was localized downstream to the mass, and was thus available for quantitative analysis. In criterion (b), the focal type was defined as the presence of a single focal mass involving less than half of the total pancreas on MRI. Cases with a mass involving > 50% pancreas (i.e., diffuse type) or multiple masses involving ≥ 2 sites (i.e., multifocal type) were excluded. Among the 36 finally included patients with focal-type AIP, 16, 5, and 15 had lesions in the head, body, and tail, respectively.
From January 2013 to December 2015, 782 patients underwent curative-intent surgery for PDA in our institution (Fig. 1). To create a 1:2 matching with the AIP group, we randomly selected 72 (49 men, 23 women; 60.5 ± 9.6 years (40–78 years)) among the 660 patients with PDA who underwent CE-MRI before surgery, using a random number generator (QuickCalcs, GraphPad Software). The presence of normal pancreatic parenchyma downstream to the mass was also considered as stated in criterion (d) of AIP. Of the 72 patients, 47, 15, and 10 had lesions in the head, body, and tail, respectively.
MRI techniques
The MRI examinations were performed using a 1.5-T unit (Magnetom Avanto; Siemens Healthineers). Transverse T2-weighted images, MR cholangiopancreatography, and transverse T1-weighted images (CE-MRI) were obtained (Table 1). The CE-MRI was obtained using three-dimensional spoiled gradient-echo sequence, including UP and dynamic triple phases at 10 s (AP), 50 s (PP), and 3 min (DP) after intravenously injecting gadoteric acid (Dotarem; Guerbet; 0.2 mmol/kg body weight) at 2 mL/s, followed by a 20-mL saline flush, using an autoinjector. Secretin was not used in any patient.
Image analysis
All images were reviewed using a local picture archiving and communication system monitor and digital imaging and communications in medicine imaging software. The patient order was randomized to avoid any patterns in the sequence of patient categories. The reviewers were blinded to the clinical data, imaging results, and final diagnosis but knew that the study population consisted of AIP and PDA.
Lesion contrast
For quantitative analysis of the lesion contrast in AIP and PDA, a board-certified abdominal radiologist performed the region-of-interest (ROI) measurement to assess the SI of the pancreatic mass and normal pancreatic parenchyma on CE-MRI. For the pancreatic mass, a round ROI was carefully placed to encompass the maximum mass area on the image wherein the mass was the most clearly visualized (Fig. 2). The peripheral enhancing portion of the mass, if present, was also included in the ROI. For the normal pancreatic parenchyma, the largest possible round ROI was carefully placed in a homogeneous region of the pancreas excluding any recognizable vessels or other non-parenchymal structures; this was performed in a downstream location to the mass to exclude any potential obstructive pancreatitis-related SI change (Fig. 2). The SI of the pancreatic mass and the normal pancreatic parenchyma was measured three times for the same image for each phase; average SI values were calculated to obtain the lesion contrast at each phase using the following equation: Contrast = SIpancreas/SImass.
For qualitative analysis of the lesion contrast, two radiologists visually assessed the CE-MRI to determine in consensus the best phase showing the largest SI difference between the mass and the normal pancreas. They also visually evaluated whether the lesion contrast changed from UP to AP (decreased, unchanged, or increased).
Key imaging features
Two radiologists reviewed all MRI examinations of the patients to determine in consensus the presence of the following key imaging features for differentiating between focal-type AIP and PDA [11,12,13,14,15,16,17,18, 22, 23]: discrete pancreatic mass (discernible focal hypointense mass with visible border between the mass and the normal pancreas) on UP and on dynamic triple phases, separately; speckled appearance (speckled hyperintense areas relative to that of the surrounding lesion on UP or AP) [15, 17]; target enhancement (layered pattern enhancement, typically a hypoenhancing lesion surrounded by hyperenhancement); delayed enhancement (hypoenhancement on AP and iso- or hyperenhancement on PP or DP compared to the normal pancreas) and pattern (homogeneous vs. heterogeneous) of the mass; halo sign (thin or thick, continuous, rim-like hypoenhancing soft tissue lesion outlining the pancreas); main pancreatic duct (MPD) stricture and its pattern (abrupt vs. tapered narrowing); duct penetrating sign (visible MPD penetrating the mass without being completely obstructed by the mass); upstream MPD dilatation (absent, mild (< 5 mm) or marked (≥ 5 mm)); and upstream pancreatic atrophy.
Statistical analysis
The lesion contrast obtained by ROI measurement at each phase of CE-MRI was compared between AIP and PDA groups using the Student t test. For the lesion contrast at each phase, the receiver operating characteristic (ROC) analysis was performed to compare the area under the ROC curve (AUROC) for distinguishing AIP from PDA among the phases. For the phase with the largest AUROC, the optimal cutoff point of the lesion contrast to maximize both the sensitivity and specificity on ROC curve (i.e., Youden index) was determined. The sensitivity and specificity of the lesion contrast at the phase when using the optimal cutoff point were compared with those of the key imaging features for the diagnosis of AIP and PDA using McNemar’s test. The frequencies of categorical variables for the qualitative analysis of the visually assessed lesion contrast and the key imaging features were compared between AIP and PDA groups using chi-square test or Fisher’s exact test, as appropriate. P < 0.05 was considered statistically significant. SPSS for Windows version 21.0 (IBM Corp.) and MedCalc for Windows version 12.5.0.0 (MedCalc) were used for the statistical analyses.
Results
Lesion contrast: AIP vs. PDA
The quantitative analysis results regarding the lesion contrast are summarized in Table 2. The lesion contrast differed significantly between AIP and PDA groups at all phases of CE-MRI (p ≤ 0.008). The lesion contrast in AIP was the highest at UP, whereas in PDA, it was the highest at AP. The dynamic pattern of the lesion contrast remarkably differed between the two groups (Fig. 3). In AIP, the lesion contrast, which was the highest at UP, gradually decreased as the phase passed. The contrast ultimately declined to less than 1.0 at DP (33 of 36, 91.7%), indicating reversal of SI between the mass and normal parenchyma. In PDA, the lesion contrast increased from UP to AP and progressively decreased thereafter. The contrast remained 1.0 or higher in most lesions (58 of 72, 80.6%) at DP in contrast with AIP. The maximum difference of the lesion contrast between AIP and PDA was observed at AP.
Table 3 shows the qualitative analysis results regarding the visually assessed lesion contrast. In AIP, the largest SI difference between the mass and the normal pancreas was observed the most frequently at UP (66.7%), followed by DP and AP. Conversely, in PDA, this maximum difference was most frequently observed at AP (69.4%). Between UP and AP, the lesion contrast decreased in 26/36 (72.2%) AIP patients, whereas it increased in 56/72 (77.8%) PDA patients. In 10 (27.8%) AIP and eight (11.1%) PDA patients, there were no perceivable contrast changes between UP and AP.
Key imaging features: AIP vs. PDA
Table 4 shows the comparative results of the key imaging features for AIP and PDA. The speckled appearance, delayed homogeneous enhancement, halo sign, MPD tapered narrowing, and duct penetrating sign were significantly more prevalent in AIP than in PDA (p < 0.001). The discrete mass on AP/PP/DP, target enhancement, MPD abrupt narrowing, upstream MPD marked dilatation, and upstream pancreatic atrophy were significantly more prevalent in PDA than in AIP (p < 0.001). The discrete mass on UP was more prevalent in PDA than in AIP; however, the difference was not statistically significant (p = 0.084). Representative cases are presented in Figs. 4 and 5.
Sensitivity and specificity for AIP and PDA: lesion contrast vs. key imaging features
Among all phases of CE-MRI, the AUROC of the lesion contrast for distinguishing AIP from PDA was the largest at AP (0.957) (Table 2) (Fig. 6). The optimal cutoff point of the lesion contrast at AP (ContrastAP) calculated by ROC analysis was 1.41. The sensitivity and specificity of ContrastAP for the diagnosis of AIP using the optimal cutoff point of 1.41 were 94.4% and 87.5%, respectively, and vice versa for PDA. Table 5 shows the comparison of these sensitivity and specificity values of ContrastAP and those of the key imaging features. Overall, both the sensitivity and specificity of ContrastAP were mostly comparable or even higher in comparison with those of the key imaging features. More specifically, the specificity of only halo sign, a key imaging feature for AIP, was significantly higher than that of ContrastAP. Otherwise, the specificity and sensitivity of ContrastAP for AIP were significantly higher than or comparable to those of the key imaging features. For PDA, the sensitivity of ContrastAP was significantly higher than those of all key imaging features, except for the discrete mass, and its specificity was also higher or comparable.
Discussion
Our study showed that the lesion contrast at AP was significantly lower in AIP than in PDA and quantitative analysis of the lesion contrast using CE-MRI could be helpful for distinguishing focal-type AIP from PDA. Our findings suggest that ContrastAP can be used as an important quantitative index for differentiating between the two diseases considering its excellent diagnostic performance when compared to those of the existing key imaging features. The sensitivity of ContrastAP (94.4%) for AIP (cutoff ≤ 1.41) was strikingly higher than that of the halo sign (38.9%). The halo sign is a representative imaging feature of AIP; however, its major drawback is poor sensitivity. In recent studies of more than 20 patients with focal-type AIP, the sensitivity of halo sign was very low at 14.6–47.5% [13,14,15]. Similarly, the duct penetrating sign also had high specificity (95.8%) but poor sensitivity (38.9%). The speckled appearance in AIP is considered to be due to the normal or less-affected pancreatic lobules within an inflammatory mass and has been reported to be specific for AIP in previous studies using CT [15] and MRI [17]. However, in this study, its specificity for AIP was only 48.6%, presumably because heterogeneous enhancement of PDA may seem similar to the speckled appearance of AIP. Among the key imaging features of AIP, delayed homogeneous enhancement was the only one with high sensitivity (80.6%) and specificity (94.4%), which were comparable to that of ContrastAP. A few previous studies comparing the enhancement patterns of focal-type or mass-forming AIP and PDA have also reported high sensitivity and specificity of delayed homogeneous enhancement [11, 16, 18], which was highlighted again in our study. Quantitative analysis of the present study also demonstrated a significant difference in delayed enhancement between the two diseases: lesion contrast at DP was less than 1.0 (i.e., SImass > SIpancreas) in 91.7% of AIP but was 1.0 or higher (i.e., SImass ≤ SIpancreas) in 80.6% of PDA. The sensitivity of ContrastAP (87.5%) for PDA (cutoff > 1.41) was significantly higher than those of all key imaging features (40.3–68.1%), except for the discrete mass, while maintaining high specificity (94.4%).
Despite the excellent diagnostic performance of ContrastAP, such quantitative analysis may be difficult to apply in actual clinical practice, which is mainly dependent on the intuitive decision by the readers based on qualitative analysis. Therefore, appropriate qualitative assessment should be supported to enhance the clinical utility of the lesion contrast-related MRI data. Two qualitative factors used to represent ContrastAP of quantitative analysis in this study were visually assessed “best phase showing the largest SI difference between the mass and the normal pancreas” and “change of the lesion contrast from UP to AP.” The results of the qualitative analysis were mostly consistent with those of the quantitative analysis. Particularly noteworthy is the change of lesion contrast from UP to AP: the contrast between lesion and the “normal” pancreas decreased in the majority of AIP, whereas it mostly increased in PDA. The sensitivity and specificity of “decrease in the visually assessed lesion contrast from UP to AP” for AIP were 72.2% and 88.9%, respectively. The sensitivity and specificity of “increase in the visually assessed lesion contrast from UP to AP” for PDA were 78.8% and 100%, respectively. In other words, between UP and AP, the lesion contrast seldom decreased in PDA, and it increased in none of AIP. Consequently, these findings may be worthy of radiologists’ attention as another key imaging feature to distinguish focal-type AIP from PDA, which can be easily applied in today’s reading environment where the readers can easily compare the images on UP and AP side by side.
Our results regarding the “discrete mass” appear to support the quantitative and qualitative analysis results of the lesion contrast. The frequency of discrete mass on AP/PP/DP (27.8%) was much lower than that on UP (66.7%) in AIP; this may indicate that it became difficult to distinguish the lesion boundary from the surrounding normal parenchyma throughout the contrast-enhanced images as the lesion enhancement starting from AP was strong to some degree. In contrast, PDA had a higher frequency of discrete mass on AP/PP/DP (95.8%) than on UP (83.3%); this result may imply that the lesion boundary was more clearly defined on contrast-enhanced images because the lesion enhancement degree was relatively weaker than the normal parenchyma, especially at AP. Several studies have quantitatively analyzed contrast enhancement using CT in patients with focal-type AIP and PDA, although they did not assess the lesion contrast [9, 16, 18]. These studies also demonstrated that the degree of contrast enhancement at the arterial or pancreatic phase was greater in AIP than in PDA, which may support our conjecture mentioned above.
The appreciable differences in the lesion contrast at AP between focal-type AIP and PDA may be explained in relation to the following pathological differences of the two diseases as suggested in previous studies [13, 17]. In PDA, there is almost no normal pancreatic tissue remaining inside the mass as the pancreatic parenchyma is almost completely replaced by tumor tissue due to carcinogenesis; moreover, tumor-related fibrosis, i.e., desmoplasia, is mostly profound. In AIP, the pancreatic parenchyma is not totally replaced by the fibrotic mass despite massive lymphoplasmacytic infiltration. Furthermore, acinar cells inside the mass are usually preserved, the lesion distribution is frequently patchy, and interstitial fibrosis is mild [13, 17, 24, 25].
Our study has a few limitations. First, there was a discrepancy in the study period between the two patient groups, i.e., 10 years for the AIP group vs. 3 years for the PDA group, which may have caused variations in the quality of MRI examinations for the AIP group. However, the longer study period for AIP patients was inevitable owing to the rarity of this disease. Second, there may be some intra- and inter-individual variations in the measured SI because the SI in MRI is not standardized, unlike Hounsfield unit in CT, and this could have slightly affected our study results.
In conclusion, the lesion contrast at AP was significantly lower in focal-type AIP than in PDA. Quantitative analysis of the lesion contrast using CE-MRI, particularly at AP, was helpful to differentiate focal-type AIP from PDA. The diagnostic performance of ContrastAP using optimal cutoff point of 1.41 was excellent and mostly comparable to or higher than those of the key imaging features. Therefore, utilization of the ContrastAP in addition to the key imaging features for differentiating between the two diseases may improve the diagnostic accuracy and help establish the prompt and appropriate treatment.
Abbreviations
- AIP:
-
Autoimmune pancreatitis
- AP:
-
Arterial phase
- AUROC:
-
Area under receiver operating characteristic curve
- CE-MRI:
-
Contrast-enhanced magnetic resonance imaging
- DP:
-
Delayed phase
- MPD:
-
Main pancreatic duct
- PDA:
-
Pancreatic ductal adenocarcinoma
- PP:
-
Portal phase
- ROC:
-
Receiver operating characteristic
- ROI:
-
Region of interest
- SI:
-
Signal intensity
- UP:
-
Unenhanced phase
References
Finkelberg DL, Sahani D, Deshpande V, Brugge WR (2006) Autoimmune pancreatitis. N Engl J Med 355:2670–2676
Chari ST, Takahashi N, Levy MJ et al (2009) A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 7:1097–1103
Kamisawa T, Imai M, Yui Chen P et al (2008) Strategy for differentiating autoimmune pancreatitis from pancreatic cancer. Pancreas 37:e62–e67
Kim JH, Kim MH, Byun JH et al (2012) Diagnostic strategy for differentiating autoimmune pancreatitis from pancreatic cancer: is an endoscopic retrograde pancreatography essential. Pancreas 41:639–647
Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N (2003) Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 98:2694–2699
Lee S, Kim JH, Kim SY et al (2018) Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Eur Radiol 28:5267–5274
Manfredi R, Frulloni L, Mantovani W, Bonatti M, Graziani R, Mucelli RP (2011) Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence. Radiology 260:428–436
Rehnitz C, Klauss M, Singer R et al (2011) Morphologic patterns of autoimmune pancreatitis in CT and MRI. Pancreatology 11:240–251
Takahashi N, Fletcher JG, Hough DM et al (2009) Autoimmune pancreatitis: differentiation from pancreatic carcinoma and normal pancreas on the basis of enhancement characteristics at dual-phase CT. AJR Am J Roentgenol 193:479–484
Wakabayashi T, Kawaura Y, Satomura Y et al (2003) Clinical and imaging features of autoimmune pancreatitis with focal pancreatic swelling or mass formation: comparison with so-called tumor-forming pancreatitis and pancreatic carcinoma. Am J Gastroenterol 98:2679–2687
Choi SY, Kim SH, Kang TW, Song KD, Park HJ, Choi YH (2016) Differentiating mass-forming autoimmune pancreatitis from pancreatic ductal adenocarcinoma on the basis of contrast-enhanced MRI and DWI findings. AJR Am J Roentgenol 206:291–300
Hur BY, Lee JM, Lee JE et al (2012) Magnetic resonance imaging findings of the mass-forming type of autoimmune pancreatitis: comparison with pancreatic adenocarcinoma. J Magn Reson Imaging 36:188–197
Kim M, Jang KM, Kim JH et al (2017) Differentiation of mass-forming focal pancreatitis from pancreatic ductal adenocarcinoma: value of characterizing dynamic enhancement patterns on contrast-enhanced MR images by adding signal intensity color mapping. Eur Radiol 27:1722–1732
Negrelli R, Manfredi R, Pedrinolla B et al (2015) Pancreatic duct abnormalities in focal autoimmune pancreatitis: MR/MRCP imaging findings. Eur Radiol 25:359–367
Furuhashi N, Suzuki K, Sakurai Y, Ikeda M, Kawai Y, Naganawa S (2015) Differentiation of focal-type autoimmune pancreatitis from pancreatic carcinoma: assessment by multiphase contrast-enhanced CT. Eur Radiol 25:1366–1374
Muhi A, Ichikawa T, Motosugi U et al (2012) Mass-forming autoimmune pancreatitis and pancreatic carcinoma: differential diagnosis on the basis of computed tomography and magnetic resonance cholangiopancreatography, and diffusion-weighted imaging findings. J Magn Reson Imaging 35:827–836
Sugiyama Y, Fujinaga Y, Kadoya M et al (2012) Characteristic magnetic resonance features of focal autoimmune pancreatitis useful for differentiation from pancreatic cancer. Jpn J Radiol 30:296–309
Sun GF, Zuo CJ, Shao CW, Wang JH, Zhang J (2013) Focal autoimmune pancreatitis: radiological characteristics help to distinguish from pancreatic cancer. World J Gastroenterol 19:3634–3641
Otsuki M, Chung JB, Okazaki K et al (2008) Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis. J Gastroenterol 43:403–408
Chari ST, Smyrk TC, Levy MJ et al (2006) Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 4:1010–1016 quiz 1934
Shimosegawa T, Chari ST, Frulloni L et al (2011) International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 40:352–358
Carbognin G, Girardi V, Biasiutti C et al (2009) Autoimmune pancreatitis: imaging findings on contrast-enhanced MR, MRCP and dynamic secretin-enhanced MRCP. Radiol Med 114:1214–1231
Chang WI, Kim BJ, Lee JK et al (2009) The clinical and radiological characteristics of focal mass-forming autoimmune pancreatitis comparison with chronic pancreatitis and pancreatic cancer. Pancreas 38:401–408
Kim HJ, Kim YK, Jeong WK, Lee WJ, Choi D (2015) Pancreatic duct "icicle sign" on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas. Eur Radiol 25:1551–1560
Chandan VS, Iacobuzio-Donahue C, Abraham SC (2008) Patchy distribution of pathologic abnormalities in autoimmune pancreatitis: implications for preoperative diagnosis. Am J Surg Pathol 32:1762–1769
Funding
The authors state that this work has not received any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Jin Hee Kim.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was waived by the Institutional Review Board.
Ethical approval
Institutional Review Board approval was obtained.
Methodology
• retrospective
• observational
• performed at one institution
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kwon, J.H., Kim, J.H., Kim, S.Y. et al. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. Eur Radiol 29, 5763–5771 (2019). https://doi.org/10.1007/s00330-019-06200-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-019-06200-0